Journal of Medical Economics study shows significant cost savings via MAF Test® – guided adjuvant bisphosphonate therapyfor early-stage breast cancer
Inbiomotion, a company commercializing its proprietary MAF Test® for identifying high risk early-stage breast cancer patients, announces the publication of a landmark economic evaluation titled “Economic impact of MAF testing for adjuvant bisphosphonate therapy in early breast cancer: a multi-regional budget impact analysis from a payer perspective” (João L. Carapinha et al.), in the Journal […]
INBRAIN Neuroelectronics Announces Collaboration to Advance Graphene-Based Brain-Computer Interfaces
INBRAIN Neuroelectronics has signed a know-how collaboration agreement with Mayo Clinic to accelerate the development and commercialization of its graphene-based brain-computer interface therapeutics (BCI-Tx). Business Wire Key points: They will evaluate the BCI-Tx platform in IRB-approved settings for neurological disorders. Business Wire INBRAIN is opening a U.S. subsidiary, starting with a Boston office, while keeping […]
Peptomyc Announces Leadership Transition to Support Next Phase of Growth
Barcelona, [July 2nd, 2025] — The Board of Directors of Peptomyc S.L., a pioneering biotech company developing innovative cancer therapies targeting the MYC oncoprotein, is pleased to announce a strategic leadership transition aimed at accelerating the company’s business development and clinical expansion efforts. Effective July 2nd, 2025, Jesus Martin Garcia will assume the role of Chief Executive Officer (CEO). […]
Accure Therapeutics awarded a total of $1.6M in grants from The Michael J. Fox Foundation and Fonds National de Recherche de Luxembourg to bring first-in-class drug for Parkinson’s disease to clinical trials
Accure Therapeutics, a private translational neuroscience R&D company, today announces its receipt of two grants totalling $1.6M for two separate development programs on its drug candidate ACT-02. ACT-02 is a novel asset with disease-modifying potential, inhibiting Prolyl Endopeptidase (PREP), a promising but previously overlooked target in Parkinson’s disease (PD). The ACT-02 program is at an […]
Peptomyc announces Research IND Approval for Innovative Window of Opportunity Trial in Collaboration with OHSU Knight Cancer Institute, Portland, Oregon, USA, in PDAC patients
Peptomyc is pleased to announce the approval of a Research Investigational New Drug (IND) application for a groundbreaking Window of Opportunity trial in collaboration with Oregon Health & Science University (OHSU) Knight Cancer Institute and Brenden-Colson Center for Pancreatic Care (BCCPC). This trial will evaluate the pharmacodynamic effects of OMO-103 in patients with pancreatic ductal […]
deepull receives FDA Breakthrough Device Designation for its UllCORE Bloodstream Infection Test
deepull, a medical diagnostics company developing culture-free diagnostic solutions for rapid pathogen identification, announced today that it has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its UllCORE Bloodstream Infection (BSI) Test. Read more
INBRAIN Neuroelectronics Raises $50M Series B to Advance Graphene-Based Brain-Computer Interface Technology
INBRAIN Neuroelectronics, a brain-computer interface therapeutics (BCI-Tx) company developing graphene-based neural technologies, today announced the close of a $50 million Series B financing round. The round was led by imec.xpand with new investors EIC Fund, Fond ICO Next Tech, CDTI-Innvierte and Avançsa. Existing investors Asabys Partners, Aliath Bioventures and Vsquared also participated, bringing the total […]
Inbiomotion and SPA – Società Prodotti Antibiotici (SPA Farma) sign an exclusive agreement for MAF Test in Italy
SPA Farma, a leading pharmaceutical company of innovative healthcare products and diagnostic tools, and Inbiomotion, proprietors of MAF Test for identifying high risk early-stage breast cancer patients, have signed an exclusive agreement to start offering the MAF Test in Italy. Read more
Ultrathin Graphene Brain Implant Was Just Tested in a Person
A Spanish biotech company sees the carbon material as a way to power the brain-computer interfaces of the future. Read more
Peptomyc Expands its Patent Portfolio with a Patent Grant in Hong Kong for its Methods and Composition for the Treatment of Cancer
Peptomyc S.L., a company developing foundational mini-protein therapeutics for the treatment of cancer, announces today that the Company has been issued a patent by the Hong Kong Patent Office protecting its Methods and Composition of Matter. Read more
